---

Background & Objective: Neural tube defects, growth retardation and nail hypoplasia are most common features of teratogenic effects of carbamazepine. This study was done to determine the effects of carbomazepine on eye development in Mice fetuses. Materials & Methods: In this experimental study 40 BALB/c pregnant Mice were divided into four groups. Experimental groups I and II received 15 mg/kg daily 6-15 GD (gestational days) and 30 mg/kg daily 6-15 GD intraperitoneal of carbamazepine, respectively. All drugs recolved in Tween20. Two control groups received normal saline or Tween 20. Dams were dissected on GD18 and embryos were collected. After observation of eye malformation in fetuses, we employed routine histological processes to stain the samples and also skeletal staining was performed. Results: Calvaria deformations, finger anomalies, brachygnathia and short tail in experimental groups I and II were 7% and 10.8%, 13.3% and 16.6%, 7.8% and 11.7%, 10.2% and 9.2% respectively. Ten of fetuses (8.6%) in experimental group I and nine of fetuses (7.5%) in the experimental group II had eye malformations. Premature opening of one or both eyes with mild to severe exophthalmos occurred in both of the experimental groups. Also, histological examination showed deformed lens, retinal folds with undeveloped layers, corneal fold with absence of surface epithelium. Conclusion: This study revealed that administration of carbamazepine during embryunic period can induce eye malformations in Mice fetuses.

---

Background and Objective: Carbamazepine (CBZ) is an antiepileptic drug that causes significant malformations such as neural tube defects (NTDs), cardiac, skeletal and craniofacial defects if it is consumed during pregnancy. The aim of this study was to evaluate the protective effect of folic acid on prevention of birth defect due to Carbamazepine in Balb/c mice. Materials and Methods: In this experimental study, Sixty Balb/c timed-pregnant mice were divided into 4 experimental and 2 control groups. Two experimental groups received daily intraperitoneal injections of 30 mg/kg (group I) and 60 mg/kg/body weight (group II) of CBZ on gestational days (GD) 6 to 15. Two other experimental groups (group III and IV) received similar doses of CBZ with folic acid supplement (3 mg/kg/day) by gavages route for 10 days before pregnancy and 15 days after GD0 (gestational day 0). Two control groups received normal saline or Tween 20 (polysorbate 20). Dams underwent cesarean section on GD18 and embryos were collected. External examination was done and data concerning malformations, weight and crown- rump of fetuses were collected and analyzed by using SPSS-11.5 software and ANOVA and chi-square tests. Results: The mean weight and crown-rump of the fetuses in both experimental groups I and II were significantly reduced. Also in both experimental groups I and II various malformations were detected such as open eyes, limb defects, scoliosis, facial deformity and NTDs. The mean weight and crown-rump of fetuses in the folic acid treated groups did not show any meaningful differences in comparison with fetuses in experimental groups I and II. Also, meaningful reductions in eye, vertebral, limb and facial defects were seen in fetuses of group III. In experimental group IV, reduction of vertebral and limb defects were observed. Conclusion: This study showed that consumption of folic acid (3 mg/kg/body weight) before and during pregnancy can reduce birth defects due to CBZ in Balb/c mice fetus.

---

Background and Objective: Carbamazepine during pregnancy can induce various malformations. Recent studies have showed an increase in homocysteine level due to Carbamazepine administration. This study was to evaluate the effect of Carbamazepine on homocysteine serum level in pregnant mice and fetal malformations outcome. Materials and Methods: In this experimental study, 40 BALB/c timed-pregnant mice were allocated into 2 experimental and 2 control groups. The experimental groups were received daily intraperitoneal injections of 30 mg/kg (group I) or 60 mg/kg (group II) of Carbamazepine on gestational days 6 to 15. The control groups were received either - normal saline or Tween 20. Dams underwent Cesarean section on GD 18. External examinations were done and all data concerning malformations, weight and crown-rump of fetuses collected. Blood samples were collected from Dams' hearts prior to performing the Cesarean section. Homocysteine was measured using ELISA method. Data were analyzed using SPSS-18, ANOVA, Chi-Square and Tukey tests. Results: Significant increase in Homocysteine levels of dams’ serum compared to control groups was seen in both experimental groups I and II (10.56±1.31 and 11.11±1.64 µmol/L, respectively, P<0.05). The mean weight and crown-rump of the fetuses in both experimental groups were significantly reduced compared with those of the control groups (P<0.05). Various malformations such as limb defects, vertebral defects, facial deformity and severe malformations were observed in fetuses of both experimental groups. Conclusion: Serum elevation of homocysteine in Carbamazepine exposed pregnant mice may be a risk factor for induction of fetal malformations.